Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(17%)
Results Posted
60%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
1
8%
Ph early_phase_1
1
8%
Ph phase_4
1
8%
Ph phase_3
1
8%
Ph not_applicable
6
50%
Ph phase_2
1
8%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
1(9.1%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
1(9.1%)
N/ANon-phased studies
6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(5)
Terminated(2)
Other(2)

Detailed Status

Completed5
Recruiting2
unknown2
Terminated1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (9.1%)
Phase 11 (9.1%)
Phase 21 (9.1%)
Phase 31 (9.1%)
Phase 41 (9.1%)
N/A6 (54.5%)

Trials by Status

completed542%
terminated18%
not_yet_recruiting18%
recruiting217%
unknown217%
withdrawn18%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
DRUG
Total Trials
12